Review



pearson correlation coefficient r  (DuPont de Nemours)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    DuPont de Nemours pearson correlation coefficient r
    Pearson Correlation Coefficient R, supplied by DuPont de Nemours, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pearson+correlation+coefficient+r/pearson+correlation+analysis/10__1080_slash_15320383__2025__2467237-65-6-24
    Average 90 stars, based on 1 article reviews
    pearson correlation coefficient r - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Content, Distribution, and Risk Assessment of Heavy Metals in Sandy Soils of the Ancient Yellow River Course
    Article Snippet: Heavy metal pollution characteristics in soils of the ancient Yellow River course are related to the ecological security of the whole Yellow River basin.. In this study, the soils were collected from two functional areas (artificial forest and farmland) of the ancient Yellow River course in Yuanyang, Henan.. The sand percentage was greater than 58%, and the soil was weakly alkaline with low organic matter content in the study area.



    Similar Products

    pearson's correlation coefficient (r) test  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson's correlation coefficient (r) test
    Pearson's Correlation Coefficient (R) Test, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pearson+correlation+coefficient+r/correlation+coefficient/us12306192-518-11-18
    Average 90 stars, based on 1 article reviews
    pearson's correlation coefficient (r) test - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    pearson’s correlation coefficient(r) calculated in graphpad prism  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson’s correlation coefficient(r) calculated in graphpad prism
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson’s Correlation Coefficient(r) Calculated In Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pearson+correlation+coefficient+r/correlation+coefficient/pmc12064836-34-6-11
    Average 90 stars, based on 1 article reviews
    pearson’s correlation coefficient(r) calculated in graphpad prism - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    squared pearson correlation coefficient (r 2)  (GraphPad Software Inc)
    90
    GraphPad Software Inc squared pearson correlation coefficient (r 2)
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Squared Pearson Correlation Coefficient (R 2), supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pearson+correlation+coefficient+r/pearson+correlation+coefficient/pmc12028599-196-6-13
    Average 90 stars, based on 1 article reviews
    squared pearson correlation coefficient (r 2) - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    pearson correlation coefficient (r) using r studio  (RStudio)
    90
    RStudio pearson correlation coefficient (r) using r studio
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson Correlation Coefficient (R) Using R Studio, supplied by RStudio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pearson+correlation+coefficient+r/pearson+correlation/pm40114072-189-0-5
    Average 90 stars, based on 1 article reviews
    pearson correlation coefficient (r) using r studio - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    pearson correlation coefficient r  (DuPont de Nemours)
    90
    DuPont de Nemours pearson correlation coefficient r
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson Correlation Coefficient R, supplied by DuPont de Nemours, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pearson+correlation+coefficient+r/pearson+correlation+analysis/10__1080_slash_15320383__2025__2467237-65-6-24
    Average 90 stars, based on 1 article reviews
    pearson correlation coefficient r - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    pearson correlation coefficient (r) with  (MathWorks Inc)
    90
    MathWorks Inc pearson correlation coefficient (r) with
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson Correlation Coefficient (R) With, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pearson+correlation+coefficient+r/pmc11817788-331-11-16
    Average 90 stars, based on 1 article reviews
    pearson correlation coefficient (r) with - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    pearson’s correlation coefficient (r)  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson’s correlation coefficient (r)
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson’s Correlation Coefficient (R), supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pearson+correlation+coefficient+r/pearson+correlation+coefficient/pmc11684645-76-7-32
    Average 90 stars, based on 1 article reviews
    pearson’s correlation coefficient (r) - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    pearson correlation coefficient (r) analysis and p value (t-distribution with n-2 degrees of freedom) calculation  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson correlation coefficient (r) analysis and p value (t-distribution with n-2 degrees of freedom) calculation
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson Correlation Coefficient (R) Analysis And P Value (T Distribution With N 2 Degrees Of Freedom) Calculation, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pearson+correlation+coefficient+r/correlation+coefficient/pmc11607453__41467_2024_54645_MOESM1_ESM-149-6-18
    Average 90 stars, based on 1 article reviews
    pearson correlation coefficient (r) analysis and p value (t-distribution with n-2 degrees of freedom) calculation - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    pearson's correlation coefficient (r) with p values calculated using graphpad prism  (GraphPad Software Inc)
    90
    GraphPad Software Inc pearson's correlation coefficient (r) with p values calculated using graphpad prism
    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using <t>Pearson’s</t> correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.
    Pearson's Correlation Coefficient (R) With P Values Calculated Using Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pearson+correlation+coefficient+r/correlation+coefficient/pm39562655-321-14-14
    Average 90 stars, based on 1 article reviews
    pearson's correlation coefficient (r) with p values calculated using graphpad prism - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer

    doi: 10.1038/s41467-025-59588-3

    Figure Lengend Snippet: a , b Scatterplot showing the relationship between gene-level alteration frequencies in ctDNA and archival tissues from ( a ) 141 patients who received prior anti-VEGF therapies, and ( b )113 patients who received prior anti-EGFR therapies. The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies. Alterations that were absent from tumor tissue samples but detected in plasma samples were defined as emerging alterations. (All genes with at least one emerging alteration listed). Only known and likely oncogenic alterations in each gene were considered for the analysis. P- value was calculated using a two-tailed Fisher’s exact test to compare the percentage of patients with emerging alterations between those who received anti-EGFR therapies and those who received anti-VEGF therapies. Source data are provided as a Source Data file.

    Article Snippet: The effect size was estimated using Pearson’s correlation coefficient(r) calculated in GraphPad Prism, and the coefficient of determination (r 2 ), representing the proportion of variance explained by the relationship, is displayed on the scatter plot. c Comparison of percentage of patients with emerging alterations between patients with prior anti-EGFR therapies and those with prior anti-VEGF therapies.

    Techniques: Comparison, Clinical Proteomics, Two Tailed Test